Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829048 · ClinicalTrials.gov registry record · Phase 1
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT01829048 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 37 participants.
The verdict
NCT01829048, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.
Interventions
- DRUG Placebo
- DRUG PF-02545920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-03-06 |
| Est. Completion | 2013-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829048
The ClinicalTrials.gov registry entry for NCT01829048 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01829048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01829048 about?
NCT01829048 is a clinical study titled "A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia". To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.
What is the current status of trial NCT01829048?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2013-03-06. Estimated completion is 2013-10-17.
What interventions are being tested in trial NCT01829048?
The interventions under investigation include: Placebo (DRUG), PF-02545920 (DRUG).
Who is sponsoring clinical trial NCT01829048?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.